⌕
Acadia Pharmaceuticals · ACAD · Nasdaq
Tenet 65 · Solid
Compare
$18.32−1.87%At closeTenet 65 · Solid
$18.32−0.35 (−1.87%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Acadia Pharmaceuticals (ACAD) Stock

Acadia Pharmaceuticals (ACAD) closed at $18.32 on Nov 17, 2026; its Tenet Score is 65 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

7 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$18.32
Nov 17, 2026
Market cap
$3.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
9.0×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
15.86 – 30.96
low → high · as of close, Nov 16, 2026
Tenet Score
65/100
Solid · 340 Healthcare peers

Industry: Drugs

Acadia Pharmaceuticals Inc scores 65/100. Solid. Strongest on financial health and quality, trading at 9× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
65/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
64
Quality
66
Health
70
Growth
59

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityCHealthBGrowthCMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
2.3×
Sep 30, 2026 balance sheet
P/S
2.7×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
31%
TTM through Sep 30, 2026
Operating margin
9.8%
fiscal 2025, before interest and tax
Net margin
30.1%
TTM through Sep 30, 2026
Current ratio
3.82
Sep 30, 2026 balance sheet
Net debt / EBITDA
−7.3×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Acadia Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treat…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 129 US ETFs · top wrappers by weightSee all ETFs holding ACAD →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Acadia Pharmaceuticals in?

Acadia Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Acadia Pharmaceuticals' Tenet Score?

Acadia Pharmaceuticals' Tenet Score is 65 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.